Parkinson's disease: From synaptic loss to connectome dysfunction

Neuropathology and Applied Neurobiology

Volumn 42, Issue 1, 2016, Pages 77-94

  Bellucci, Arianna ^a   Mercuri, Nicola Biagio ^b   Venneri, Annalena ^c,d   Faustini, Gaia ^a   Longhena, Francesca ^a   Pizzi, Marina ^a,c   Missale, Cristina ^a   Spano, Pierfranco ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS Fondazione Ospedale San Camillo (NHS Italy)   (Italy)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Axonal damage; Functional connectome; Parkinson's disease; Synaptic loss; synuclein

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE;

CELL INCLUSION; CLINICAL FEATURE; COMORBIDITY; CONNECTOME; DISEASE COURSE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; LEWY BODY; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER GROWTH; NERVE FIBER TRANSPORT; NEUROTRANSMITTER RELEASE; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW; SYNAPSE; SYNAPSE VESICLE; HUMAN; PATHOLOGY;

CONNECTOME; DISEASE PROGRESSION; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE; SYNAPSES;

EID: 84959240232     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12297     Document Type: Review

References (177)

1. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-76.
2. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 1998; 95: 6469-73.
3. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-74.
4. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011; 17: 717-23.
5. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104: 380-6.
6. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-81.
7. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845-51.
8. Jacob EL, Gatto NM, Thompson A, Bordelon Y, Ritz B. Occurrence of depression and anxiety prior to Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 576-81.
9. del TK, Rub U, de Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413-26.
10. Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of the striatum in Parkinson's disease. Brain 2012; 135: 3699-711.
11. Prodoehl J, Burciu RG, Vaillancourt DE. Resting state functional magnetic resonance imaging in Parkinson's disease. Curr Neurol Neurosci Rep 2014; 14: 448.
12. Luo C, Song W, Chen Q, Zheng Z, Chen K, Cao B, Yang J, Li J, Huang X, Gong Q, Shang HF. Reduced functional connectivity in early-stage drug-naive Parkinson's disease: a resting-state fMRI study. Neurobiol Aging 2014; 35: 431-41.
13. Olde Dubbelink KT, Stoffers D, Deijen JB, Twisk JW, Stam CJ, Hillebrand A, Berendse HW. Resting-state functional connectivity as a marker of disease progression in Parkinson's disease: A longitudinal MEG study. Neuroimage Clin 2013; 2: 612-9.
14. Wang J, Yang QX, Sun X, Vesek J, Mosher Z, Vasavada M, Chu J, Kanekar S, Shivkumar V, Venkiteswaran K, Subramanian T. MRI evaluation of asymmetry of nigrostriatal damage in the early stage of early-onset Parkinson's disease. Parkinsonism Relat Disord 2015; 21: 590-6.
15. Auning E, Selnes P, Grambaite R, Saltyte BJ, Haram A, Lovli SA, Bjornerud A, Hessen E, Hol PK, Muftuler lA, Fladby T, Aarsland D. Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. Acta Psychiatr Scand 2015; 131: 139-47.
16. Gu Q, Huang P, Xuan M, Xu X, Li D, Sun J, Yu H, Wang C, Luo W, Zhang M. Greater loss of white matter integrity in postural instability and gait difficulty subtype of Parkinson's disease. Can J Neurol Sci 2014; 41: 763-8.
17. Gattellaro G, Minati L, Grisoli M, Mariani C, Carella F, Osio M, Ciceri E, Albanese A, Bruzzone MG. White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. AJNR Am J Neuroradiol 2009; 30: 1222-6.
18. Zhang J, Wei L, Hu X, Xie B, Zhang Y, Wu GR, Wang J. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of intrinsic brain activity. Parkinsonism Relat Disord 2015; 21: 23-30.
19. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009; 15(Suppl 3): S1-5.
20. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol 2011; 95: 614-28.
21. Braak H. del TK, Rub U, de Vos RA, Jansen Steur EN, and Braak E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
22. Sian-Hulsmann J, Monoranu C, Strobel S, Riederer P. Lewy bodies: A spectator or salient killer?. CNS Neurol Disord Drug Targets 2015; 14: 947-55.
23. Dijkstra AA, Voorn P, Berendse HW, Groenewegen HJ, Rozemuller AJ, van de Berg WD. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Mov Disord 2014; 29: 1244-51.
24. van de Berg WD, Hepp DH, Dijkstra AA, Rozemuller JA, Berendse HW, Foncke E. Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease. Parkinsonism Relat Disord 2012; 18(Suppl 1): S28-30.
25. Braak H, del TK. A new look at the corticostriatal-thalamocortical circuit in sporadic Parkinson's disease. Nervenarzt 2008; 79: 1440-5.
26. Hunn BH, Cragg SJ, Bolam JP, Spillantini MG, Wade-Martins R. Impaired intracellular trafficking defines early Parkinson's disease. Trends Neurosci 2015; 38: 178-88.
27. Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord 2012; 27: 1478-83.
28. Pissadaki EK, Bolam JP. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front Comput Neurosci 2013; 7: 13.
29. Dijkstra AA, Ingrassia A, de Menezes RX, van Kesteren RE, Rozemuller AJ, Heutink P, van de Berg WD. Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson's Disease. PLoS ONE 2015; 10: e0128651.
30. Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, Spano P. From alpha-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res 2012; 1476: 183-202.
31. Anichtchik O, Calo L, Spillantini MG. Synaptic dysfunction in synucleinopathies. CNS Neurol Disord Drug Targets 2013; 12: 1094-100.
32. Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 2015; 14: 855-66.
33. Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, Di Monte DA, Uversky VN, Fink AL. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 2003; 42: 8465-71.
34. Gai WP, Power JH, Blumbergs PC, Blessing WW. Multiple-system atrophy: a new alpha-synuclein disease? Lancet 1998; 352: 547-8.
35. Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol 1999; 58: 1263-8.
36. Roberts RF, Wade-Martins R, egre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 2015; 138: 1642-57.
37. Gadad BS, Britton GB, Rao KS. Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide. J Alzheimers Dis 2011; 24(Suppl 2): 223-32.
38. Gallegos S, Pacheco C, Peters C, Opazo CM, Aguayo LG. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Front Neurosci 2015; 9: 59.
39. Smith WW, Jiang H, Pei Z, Tanaka Y, Morita H, Sawa A, Dawson VL, Dawson TM, Ross CA. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 2005; 14: 3801-11.
40. Illes-Toth E, Ramos MR, Cappai R, Dalton C, Smith DP. Distinct higher-order α-synuclein oligomers induce intracellular aggregation. Biochem J 2015; 468: 485-93.
41. Bae EJ, Ho DH, Park E, Jung JW, Cho K, Hong JH, Lee HJ, Kim KP, Lee SJ. Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of alpha-synuclein. Antioxid Redox Signal 2013; 18: 770-83.
42. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 2012; 7: 42.
43. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, McLean PJ. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 2011; 25: 326-36.
44. Lee SJ, Desplats P, Lee HJ, Spencer B, Masliah E. Cell-to-cell transmission of alpha-synuclein aggregates. Methods Mol Biol 2012; 849: 347-59.
45. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010; 6: 702-6.
46. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-5.
47. Braidy N, Gai WP, Xu YH, Sachdev P, Guillemin GJ, Jiang XM, Ballard JW, Horan MP, Fang ZM, Chong BH, Chan DK. Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl Neurodegener 2013; 2: 20.
48. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M, Melki R, Kirkegaard K, Brahic M. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol 2012; 72: 517-24.
49. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 2008; 23: 2303-6.
50. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, Sortwell C, Steece-Collier K, Collier TJ. Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 2011; 43: 552-7.
51. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949-53.
52. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012; 209: 975-86.
53. Peelaerts W, Bousset L, Van der PA, Moskalyuk A, Pulizzi R, Giugliano M, Van den HC, Melki R, Baekelandt V. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015; 522: 340-4.
54. Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 2014; 8: 159.
55. Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, Marti MJ, Hernandez I, Valldeoriola F, Rene R, Ribalta T. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014; 29: 1010-8.
56. Hoepken HH, Gispert S, Azizov M, Klinkenberg M, Ricciardi F, Kurz A, Morales-Gordo B, Bonin M, Riess O, Gasser T, Kogel D, Steinmetz H, Auburger G. Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 2008; 212: 307-13.
57. Grathwohl SA, Steiner JA, Britschgi M, Brundin P. Mind the gut: secretion of alpha-synuclein by enteric neurons. J Neurochem 2013; 125: 487-90.
58. Holmqvist S, Chutna O, Bousset L, drin-Kirk P, Li W, Bjorklund T, Wang ZY, Roybon L, Melki R, Li JY. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 2014; 128: 805-20.
59. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol 2008; 116: 125-8.
60. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010; 1184: 188-95.
61. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; 386: 896-912.
62. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del ST, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
63. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102: 355-63.
64. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-9.
65. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611-5.
66. Buter TC, van den HA, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017-22.
67. Pagonabarraga J, Kulisevsky J. Cognitive impairment and dementia in Parkinson's disease. Neurobiol Dis 2012; 46: 590-6.
68. Post B, Merkus MP, de Haan RJ, Speelman JD. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 2007; 22: 1839-51.
69. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-57.
70. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55: 174-9.
71. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008; 63: 743-50.
72. Ibanez P, Lesage S, Janin S, Lohmann E, Durif F, Destee A, Bonnet AM, Brefel-Courbon C, Heath S, Zelenika D, Agid Y, Durr A, Brice A. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 2009; 66: 102-8.
73. Ritz B, Rhodes SL, Bordelon Y, Bronstein J. alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS ONE 2012; 7: e36199.
74. Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014; 184: 966-75.
75. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713-26.
76. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349: 162-6.
77. Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Bostrom F, Hansson O, Nielsen HM. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013; 8: e53250.
78. Koehler NK, Stransky E, Meyer M, Gaertner S, Shing M, Schnaidt M, Celej MS, Jovin TM, Leyhe T, Laske C, Batra A, Buchkremer G, Fallgatter AJ, Wernet D, Richartz-Salzburger E. Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS ONE 2015; 10: e0123444.
79. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20: 419-25.
80. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011; 7: 215-22.
81. Compta Y, Valente T, Saura J, Segura B, Iranzo A, Serradell M, Junque C, Tolosa E, Valldeoriola F, Munoz E, Santamaria J, Camara A, Fernandez M, Fortea J, Buongiorno M, Molinuevo JL, Bargallo N, Marti MJ. Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. J Neurol 2015; 262: 294-306.
82. Mollenhauer B. Quantification of alpha-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease? Parkinsonism Relat Disord 2014; 20(Suppl 1): S76-9.
83. Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, Capellari S, Avoni P, Baruzzi A, Liguori R. Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014; 82: 1362-9.
84. Cersosimo MG. Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease. Gastroenterol Res Pract 2015; 2015: 476041.
85. Visanji NP, Marras C, Kern DS, Al DA, Gao A, Liu LW, Lang AE, Hazrati LN. Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015; 84: 609-16.
86. Adler CH, Dugger BN, Hinni ML, Lott DG, Driver-Dunckley E, Hidalgo J, Henry-Watson J, Serrano G, Sue LI, Nagel T, Duffy A, Shill HA, Akiyama H, Walker DG, Beach TG. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 2014; 82: 858-64.
87. Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci 2014; 34: 9441-54.
88. Toth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet JC, Galvagnion C, Skibinski G, Finkbeiner S, Bova M, Regnstrom K, Chiou SS, Johnston J, Callaway K, Anderson JP, Jobling MF, Buell AK, Yednock TA, Knowles TP, Vendruscolo M, Christodoulou J, Dobson CM, Schenk D, McConlogue L. Targeting the intrinsically disordered structural ensemble of alpha-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS ONE 2014; 9: e87133.
89. Di NM. New molecular avenues in Parkinson's disease therapy. Curr Top Med Chem 2009; 9: 913-48.
90. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857-68.
91. Zaltieri M, Grigoletto J, Longhena F, Navarria L, Favero G, Castrezzati S, Colivicchi MA, Della CL, Rezzani R, Pizzi M, Benfenati F, Spillantini MG, Missale C, Spano P, Bellucci A. alpha-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. J Cell Sci 2015; 128: 2231-43.
92. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009; 132: 1795-809.
93. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120: 131-43.
94. Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol 2014; 88: 508-16.
95. Zaltieri M, Longhena F, Pizzi M, Missale C, Spano P, Bellucci A. Mitochondrial Dysfunction and alpha-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? Parkinsons Dis 2015; 2015: 108029.
96. Kitada T, Tong Y, Gautier CA, Shen J. Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 2009; 111: 696-702.
97. Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini PP. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 2004; 127: 1332-42.
98. Chou JS, Chen CY, Chen YL, Weng YH, Yeh TH, Lu CS, Chang YM, Wang HL. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Neurobiol Dis 2014; 68: 190-9.
99. Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao LP, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet 2015; 24: 1336-49.
100. Madeo G, Schirinzi T, Martella G, Latagliata EC, Puglisi F, Shen J, Valente EM, Federici M, Mercuri NB, Puglisi-Allegra S, Bonsi P, Pisani A. PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. Mov Disord 2014; 29: 41-53.
101. Wilson GR, Sim JC, McLean C, Giannandrea M, Galea CA, Riseley JR, Stephenson SE, Fitzpatrick E, Haas SA, Pope K, Hogan KJ, Gregg RG, Bromhead CJ, Wargowski DS, Lawrence CH, James PA, Churchyard A, Gao Y, Phelan DG, Gillies G, Salce N, Stanford L, Marsh AP, Mignogna ML, Hayflick SJ, Leventer RJ, Delatycki MB, Mellick GD, Kalscheuer VM, D'Adamo P, Bahlo M, Amor DJ, Lockhart PJ. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with alpha-synuclein pathology. Am J Hum Genet 2014; 95: 729-35.
102. Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, Rajput AH, Hornykiewicz O. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci 2014; 34: 8210-8.
103. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999; 156: 138-48.
104. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997; 41: 530-9.
105. Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov Disord 1997; 12: 885-97.
106. Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov Disord 2008; 23: 1608-12.
107. Yamamoto S, Fukae J, Mori H, Mizuno Y, Hattori N. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra. Neurosci Lett 2006; 396: 187-91.
108. Ben GT, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R. Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 2009; 10: 218-34.
109. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010; 65: 66-79.
110. Cheng F, Vivacqua G, Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat 2011; 42: 242-8.
111. Diao J, Burre J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Sudhof TC, Brunger AT. Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2013; 2: e00592.
112. Chen RH, Wislet-Gendebien S, Samuel F, Visanji NP, Zhang G, Marsilio D, Langman T, Fraser PE, Tandon A. alpha-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J Biol Chem 2013; 288: 7438-49.
113. Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci 2014; 34: 9364-76.
114. Burre J, Vivona S, Diao J, Sharma M, Brunger AT, Sudhof TC. Properties of native brain alpha-synuclein. Nature 2013; 498: E4-6.
115. Lai Y, Kim S, Varkey J, Lou X, Song JK, Diao J, Langen R, Shin YK. Nonaggregated alpha-synuclein influences SNARE-dependent vesicle docking via membrane binding. Biochemistry 2014; 53: 3889-96.
116. Choi BK, Kim JY, Cha MY, Mook-Jung I, Shin YK, Lee NK. beta-Amyloid and alpha-synuclein cooperate to block SNARE-dependent vesicle fusion. Biochemistry 2015; 54: 1831-40.
117. Garcia-Reitbock P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della CL, Spano P, Tofaris GK, Goedert M, Spillantini MG. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 2010; 133: 2032-44.
118. Kile BM, Guillot TS, Venton BJ, Wetsel WC, Augustine GJ, Wightman RM. Synapsins differentially control dopamine and serotonin release. J Neurosci 2010; 30: 9762-70.
119. Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J Neurochem 2008; 106: 560-77.
120. Bellucci A, Navarria L, Falarti E, Zaltieri M, Bono F, Collo G, Spillantini MG, Missale C, Spano P. Redistribution of DAT/alpha-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS ONE 2011; 6: e27959.
121. Wersinger C, Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 2003; 340: 189-92.
122. Betzer C, Movius AJ, Shi M, Gai WP, Zhang J, Jensen PH. Identification of synaptosomal proteins binding to monomeric and oligomeric alpha-synuclein. PLoS ONE 2015; 10: e0116473.
123. Bogen IL, Boulland JL, Mariussen E, Wright MS, Fonnum F, Kao HT, Walaas SI. Absence of synapsin I and II is accompanied by decreases in vesicular transport of specific neurotransmitters. J Neurochem 2006; 96: 1458-66.
124. Chutna O, Goncalves S, Villar-Pique A, Guerreiro P, Marijanovic Z, Mendes T, Ramalho J, Emmanouilidou E, Ventura S, Klucken J, Barral DC, Giorgini F, Vekrellis K, Outeiro TF. The small GTPase Rab11 co-localizes with alpha-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Hum Mol Genet 2014; 23: 6732-45.
125. Breda C, Nugent ML, Estranero JG, Kyriacou CP, Outeiro TF, Steinert JR, Giorgini F. Rab11 modulates alpha-synuclein-mediated defects in synaptic transmission and behaviour. Hum Mol Genet 2015; 24: 1077-91.
126. Yin G, da Lopes FT, Eisbach SE, Anduaga AM, Breda C, Orcellet ML, Szego EM, Guerreiro P, Lazaro DF, Braus GH, Fernandez CO, Griesinger C, Becker S, Goody RS, Itzen A, Giorgini F, Outeiro TF, Zweckstetter M. alpha-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. Neurobiol Dis 2014; 70: 149-61.
127. Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, Chen S, Zhang J. Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci 2009; 29: 1480-5.
128. Volpicelli-Daley LA, Gamble KL, Schultheiss CE, Riddle DM, West AB, Lee VM. Formation of alpha-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol Biol Cell 2014; 25: 4010-23.
129. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, Caldwell KA, Caldwell GA, Rochet JC, McCaffery JM, Barlowe C, Lindquist S. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 2008; 105: 145-50.
130. Eva R, Dassie E, Caswell PT, Dick G. ffrench-Constant C, Norman JC, and Fawcett JW: Rab11 and its effector Rab coupling protein contribute to the trafficking of beta 1 integrins during axon growth in adult dorsal root ganglion neurons and PC12 cells. J Neurosci 2010; 30: 11654-69.
131. Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, Bucci C, Schiavo G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron 2006; 52: 293-305.
132. Villarroel-Campos D, Gastaldi L, Conde C, Caceres A, Gonzalez-Billault C. Rab-mediated trafficking role in neurite formation. J Neurochem 2014; 129: 240-8.
133. Zhang K, Fishel Ben KR, Osakada Y, Xu W, Sinit RS, Chen L, Zhao X, Chen JY, Cui B, Wu C. Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J Neurosci 2013; 33: 7451-62.
134. Piccoli G, Onofri F, Cirnaru MD, Kaiser CJ, Jagtap P, Kastenmuller A, Pischedda F, Marte A, von ZF, Vogt A, Giesert F, Pan L, Antonucci F, Kiel C, Zhang M, Weinkauf S, Sattler M, Sala C, Matteoli M, Ueffing M, Gloeckner CJ. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol Cell Biol 2014; 34: 2147-61.
135. Liu HF, Lu S, Ho PW, Tse HM, Pang SY, Kung MH, Ho JW, Ramsden DB, Zhou ZJ, Ho SL. LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity. Ann Clin Transl Neurol 2014; 1: 199-208.
136. Liu G, Sgobio C, Gu X, Sun L, Lin X, Yu J, Parisiadou L, Xie C, Sastry N, Ding J, Lohr KM, Miller GW, Mateo Y, Lovinger DM, Cai H. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Hum Mol Genet 2015; 24: 5299-312.
137. Periquet M, Corti O, Jacquier S, Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 2005; 95: 1259-76.
138. Rial D, Castro AA, Machado N, Garcao P, Goncalves FQ, Silva HB, Tome AR, Kofalvi A, Corti O, Raisman-Vozari R, Cunha RA, Prediger RD. Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease. PLoS ONE 2014; 9: e114216.
139. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003; 278: 43628-35.
140. Usami Y, Hatano T, Imai S, Kubo S, Sato S, Saiki S, Fujioka Y, Ohba Y, Sato F, Funayama M, Eguchi H, Shiba K, Ariga H, Shen J, Hattori N. DJ-1 associates with synaptic membranes. Neurobiol Dis 2011; 43: 651-62.
141. Wang Y, Chandran JS, Cai H, Mattson MP. DJ-1 is essential for long-term depression at hippocampal CA1 synapses. Neuromolecular Med 2008; 10: 40-5.
142. Manning-Bog AB, Caudle WM, Perez XA, Reaney SH, Paletzki R, Isla MZ, Chou VP, McCormack AL, Miller GW, Langston JW, Gerfen CR, Dimonte DA. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis 2007; 27: 141-50.
143. Krebs CE, Karkheiran S, Powell JC, Cao M, Makarov V, Darvish H, Di PG, Walker RH, Shahidi GA, Buxbaum JD, De CP, Yue Z, Paisan-Ruiz C. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum Mutat 2013; 34: 1200-7.
144. Munsie LN, Milnerwood AJ, Seibler P, Beccano-Kelly DA, Tatarnikov I, Khinda J, Volta M, Kadgien C, Cao LP, Tapia L, Klein C, Farrer MJ. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p. D620N. Hum Mol Genet 2015; 24: 1691-703.
145. Butz M, Worgotter F, van OA. Activity-dependent structural plasticity. Brain Res Rev 2009; 60: 287-305.
146. Chklovskii DB. Synaptic connectivity and neuronal morphology: two sides of the same coin. Neuron 2004; 43: 609-17.
147. Hering H, Sheng M. Dendritic spines: structure, dynamics and regulation. Nat Rev Neurosci 2001; 2: 880-8.
148. Fauth M, Worgotter F, Tetzlaff C. The formation of multi-synaptic connections by the interaction of synaptic and structural plasticity and their functional consequences. PLoS Comput Biol 2015; 11: e1004031.
149. Bi G, Poo M. Synaptic modification by correlated activity: Hebb's postulate revisited. Annu Rev Neurosci 2001; 24: 139-66.
150. Turrigiano GG, Nelson SB. Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci 2004; 5: 97-107.
151. Le Be JV, Markram H. Spontaneous and evoked synaptic rewiring in the neonatal neocortex. Proc Natl Acad Sci U S A 2006; 103: 13214-9.
152. Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, Svoboda K. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 2002; 420: 788-94.
153. Yasumatsu N, Matsuzaki M, Miyazaki T, Noguchi J, Kasai H. Principles of long-term dynamics of dendritic spines. J Neurosci 2008; 28: 13592-608.
154. Matsuzaki M, Ellis-Davies GC, Nemoto T, Miyashita Y, Iino M, Kasai H. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat Neurosci 2001; 4: 1086-92.
155. Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature 2004; 429: 761-6.
156. Zhou Q, Homma KJ, Poo MM. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004; 44: 749-57.
157. Kelly C, Castellanos FX. Strengthening connections: functional connectivity and brain plasticity. Neuropsychol Rev 2014; 24: 63-76.
158. Lai KO, Ip NY. Structural plasticity of dendritic spines: the underlying mechanisms and its dysregulation in brain disorders. Biochim Biophys Acta 2013; 1832: 2257-63.
159. Wild AR, Jones S, Gibb AJ. Activity-dependent regulation of NMDA receptors in substantia nigra dopaminergic neurones. J Physiol 2014; 592: 653-68.
160. Loopuijt LD, Schmidt WJ. The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Amino Acids 1998; 14: 17-23.
161. Paladini CA, Roeper J. Generating bursts (and pauses) in the dopamine midbrain neurons. Neuroscience 2014; 282C: 109-21.
162. Diogenes MJ, Dias RB, Rombo DM, Vicente MH, Maiolino F, Guerreiro P, Nasstrom T, Franquelim HG, Oliveira LM, Castanho MA, Lannfelt L, Bergstrom J, Ingelsson M, Quintas A, Sebastiao AM, Lopes LV, Outeiro TF. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012; 32: 11750-62.
163. Chen Y, Yang W, Li X, Li X, Yang H, Xu Z, Yu S. alpha-Synuclein-induced internalization of NMDA receptors in hippocampal neurons is associated with reduced inward current and Ca(2+) influx upon NMDA stimulation. Neuroscience 2015; 300: 297-306.
164. Cheng F, Li X, Li Y, Wang C, Wang T, Liu G, Baskys A, Ueda K, Chan P, Yu S. alpha-Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death. J Neurochem 2011; 119: 815-25.
165. Prasad K, Beach TG, Hedreen J, Richfield EK. Critical role of truncated alpha-synuclein and aggregates in Parkinson's disease and incidental Lewy body disease. Brain Pathol 2012; 22: 811-25.
166. Navarria L, Zaltieri M, Longhena F, Spillantini MG, Missale C, Spano P, Bellucci A. Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. Neurochem Int 2015; 85-86: 14-23.
167. Espinosa JS, Wheeler DG, Tsien RW, Luo L. Uncoupling dendrite growth and patterning: single-cell knockout analysis of NMDA receptor 2B. Neuron 2009; 62: 205-17.
168. Bustos FJ, Varela-Nallar L, Campos M, Henriquez B, Phillips M, Opazo C, Aguayo LG, Montecino M, Constantine-Paton M, Inestrosa NC, van ZB. PSD95 suppresses dendritic arbor development in mature hippocampal neurons by occluding the clustering of NR2B-NMDA receptors. PLoS ONE 2014; 9: e94037.
169. Zhu Y, Pak D, Qin Y, McCormack SG, Kim MJ, Baumgart JP, Velamoor V, Auberson YP, Osten P. van AL, Sheng M, and Zhu JJ: Rap2-JNK removes synaptic AMPA receptors during depotentiation. Neuron 2005; 46: 905-16.
170. Costa RO, Lacor PN, Ferreira IL, Resende R, Auberson YP, Klein WL, Oliveira CR, Rego AC, Pereira CM. Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N-methyl-d-aspartate receptor in mature hippocampal cultures treated with amyloid-beta oligomers. Aging Cell 2012; 11: 823-33.
171. Tozzi A, de IA, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, Costa C, Di FM, Ghiglieri V, Latagliata EC, Wegrzynowicz M, Decressac M, Giampa C, Dalley JW, Xia J, Gardoni F, Mellone M, El-Agnaf OM, Ardah MT, Puglisi-Allegra S, Bjorklund A, Spillantini MG, Picconi B, Calabresi P: Alpha-Synuclein Produces Early Behavioral Alterations Via Striatal Cholinergic Synaptic Dysfunction by Interacting with GluN2D N-Methyl-D-Aspartate Receptor Subunit. Biol Psychiatry 2015, pii: S0006-3223(15)00678-2.
172. Wu J, Quinlan EB, Dodakian L, McKenzie A, Kathuria N, Zhou RJ, Augsburger R, See J, Le VH, Srinivasan R, Cramer SC. Connectivity measures are robust biomarkers of cortical function and plasticity after stroke. Brain 2015; 138: 2359-69.
173. Szewczyk-Krolikowski K, Menke RA, Rolinski M, Duff E, Salimi-Khorshidi G, Filippini N, Zamboni G, Hu MT, Mackay CE. Functional connectivity in the basal ganglia network differentiates PD patients from controls. Neurology 2014; 83: 208-14.
174. Hu X, Song X, Yuan Y, Li E, Liu J, Liu W, Liu Y. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease. Mov Disord 2015; 30: 238-44.
175. Lei X, Huang B, Li H, Jiang H, Hu X, Zhang B. Drift in centrality of different brain regions in an anatomical neural network with Parkinson's disease: A view from complex network analysis. Neuroscience 2015; 299: 107-24.
176. Yu R, Liu B, Wang L, Chen J, Liu X. Enhanced functional connectivity between putamen and supplementary motor area in Parkinson's disease patients. PLoS ONE 2013; 8: e59717.
177. Mueller C, Pinter B, Reiter E, Schocke M, Scherfler C, Poewe W, Seppi K, Blazejewska AI, Schwarz ST, Bajaj N, Auer DP, Gowland PA. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology 2014; 82: 1752.